Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatectomy | 54 | 2020 | 471 | 4.930 |
Why?
|
Robotics | 44 | 2015 | 267 | 4.570 |
Why?
|
Prostatic Neoplasms | 55 | 2021 | 1721 | 3.190 |
Why?
|
Laparoscopy | 35 | 2020 | 755 | 2.850 |
Why?
|
Erectile Dysfunction | 8 | 2010 | 73 | 0.800 |
Why?
|
Urology | 4 | 2020 | 110 | 0.750 |
Why?
|
Prostate | 10 | 2015 | 378 | 0.740 |
Why?
|
Robotic Surgical Procedures | 4 | 2020 | 268 | 0.650 |
Why?
|
Lymph Node Excision | 3 | 2015 | 217 | 0.610 |
Why?
|
Urinary Incontinence | 6 | 2012 | 206 | 0.580 |
Why?
|
Postoperative Hemorrhage | 2 | 2015 | 46 | 0.580 |
Why?
|
Surgery, Computer-Assisted | 2 | 2015 | 97 | 0.560 |
Why?
|
Middle Aged | 57 | 2020 | 24742 | 0.550 |
Why?
|
Male | 77 | 2021 | 40654 | 0.530 |
Why?
|
Head-Down Tilt | 1 | 2015 | 5 | 0.530 |
Why?
|
Adenocarcinoma | 7 | 2021 | 1168 | 0.520 |
Why?
|
Ear Diseases | 1 | 2015 | 19 | 0.520 |
Why?
|
Urinary Bladder, Neurogenic | 3 | 2011 | 25 | 0.510 |
Why?
|
Clinical Clerkship | 2 | 2007 | 116 | 0.510 |
Why?
|
Blood Loss, Surgical | 1 | 2015 | 112 | 0.500 |
Why?
|
Aged | 47 | 2021 | 18161 | 0.500 |
Why?
|
Hematoma | 1 | 2015 | 104 | 0.490 |
Why?
|
Urinary Catheters | 1 | 2014 | 6 | 0.480 |
Why?
|
Urinary Catheterization | 1 | 2014 | 35 | 0.470 |
Why?
|
Drainage | 1 | 2014 | 157 | 0.440 |
Why?
|
Device Removal | 1 | 2014 | 161 | 0.420 |
Why?
|
Curriculum | 2 | 2007 | 542 | 0.420 |
Why?
|
Urinary Diversion | 2 | 2010 | 42 | 0.410 |
Why?
|
Prospective Studies | 20 | 2014 | 4160 | 0.400 |
Why?
|
Neoplasm Staging | 16 | 2016 | 1938 | 0.400 |
Why?
|
Sural Nerve | 2 | 2008 | 19 | 0.390 |
Why?
|
Laparoscopes | 2 | 2008 | 15 | 0.390 |
Why?
|
Seminal Vesicles | 4 | 2021 | 39 | 0.390 |
Why?
|
Humans | 84 | 2021 | 85796 | 0.380 |
Why?
|
Treatment Outcome | 25 | 2020 | 7831 | 0.360 |
Why?
|
Prostatic Intraepithelial Neoplasia | 1 | 2009 | 21 | 0.340 |
Why?
|
Suture Techniques | 6 | 2010 | 134 | 0.340 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2009 | 100 | 0.320 |
Why?
|
Retrospective Studies | 18 | 2020 | 8466 | 0.320 |
Why?
|
Follow-Up Studies | 14 | 2016 | 3591 | 0.320 |
Why?
|
Urination Disorders | 4 | 2008 | 50 | 0.310 |
Why?
|
Teaching Materials | 1 | 2007 | 12 | 0.310 |
Why?
|
Preoperative Care | 6 | 2013 | 397 | 0.310 |
Why?
|
Learning | 2 | 2007 | 281 | 0.300 |
Why?
|
Equipment Failure | 1 | 2007 | 119 | 0.300 |
Why?
|
Urinary Bladder Neoplasms | 3 | 2008 | 383 | 0.280 |
Why?
|
Educational Measurement | 1 | 2007 | 225 | 0.270 |
Why?
|
Postoperative Care | 5 | 2014 | 221 | 0.260 |
Why?
|
Biopsy, Needle | 6 | 2012 | 234 | 0.230 |
Why?
|
Urethra | 2 | 2006 | 113 | 0.230 |
Why?
|
Adult | 29 | 2016 | 25522 | 0.230 |
Why?
|
Postoperative Complications | 11 | 2011 | 2204 | 0.220 |
Why?
|
Urologic Surgical Procedures | 2 | 2017 | 146 | 0.220 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2015 | 1313 | 0.220 |
Why?
|
Aged, 80 and over | 15 | 2011 | 6479 | 0.220 |
Why?
|
Carcinoma, Giant Cell | 1 | 2002 | 1 | 0.210 |
Why?
|
Multivariate Analysis | 8 | 2012 | 985 | 0.210 |
Why?
|
Vaginal Neoplasms | 1 | 2002 | 83 | 0.210 |
Why?
|
Disease-Free Survival | 6 | 2015 | 1202 | 0.200 |
Why?
|
Appendix | 3 | 2011 | 31 | 0.200 |
Why?
|
Cystadenoma | 1 | 2021 | 19 | 0.200 |
Why?
|
Prostate-Specific Antigen | 8 | 2013 | 353 | 0.200 |
Why?
|
Penile Erection | 1 | 2000 | 22 | 0.190 |
Why?
|
Margins of Excision | 1 | 2020 | 39 | 0.190 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 2000 | 30 | 0.190 |
Why?
|
Clinical Competence | 3 | 2015 | 756 | 0.190 |
Why?
|
Workload | 1 | 2020 | 128 | 0.180 |
Why?
|
Urethral Diseases | 1 | 1999 | 15 | 0.170 |
Why?
|
Ossification, Heterotopic | 1 | 1999 | 33 | 0.170 |
Why?
|
Time Factors | 8 | 2014 | 5178 | 0.170 |
Why?
|
Pelvis | 3 | 2015 | 94 | 0.170 |
Why?
|
Pelvic Bones | 1 | 1999 | 43 | 0.170 |
Why?
|
Phimosis | 1 | 1998 | 1 | 0.170 |
Why?
|
Piperazines | 1 | 2000 | 272 | 0.170 |
Why?
|
Proportional Hazards Models | 4 | 2015 | 836 | 0.160 |
Why?
|
Biopsy | 9 | 2016 | 1163 | 0.160 |
Why?
|
Surveys and Questionnaires | 8 | 2010 | 2500 | 0.160 |
Why?
|
Nomograms | 2 | 2008 | 28 | 0.160 |
Why?
|
Anastomosis, Surgical | 5 | 2011 | 267 | 0.160 |
Why?
|
Spermine | 1 | 1998 | 18 | 0.160 |
Why?
|
Urinary Bladder Neck Obstruction | 3 | 2008 | 21 | 0.160 |
Why?
|
Fractures, Bone | 1 | 1999 | 122 | 0.160 |
Why?
|
Lymphatic Metastasis | 3 | 2015 | 486 | 0.150 |
Why?
|
Health Plan Implementation | 1 | 2017 | 56 | 0.150 |
Why?
|
Tertiary Care Centers | 1 | 2017 | 94 | 0.150 |
Why?
|
Urologic Diseases | 1 | 2017 | 45 | 0.150 |
Why?
|
Urinary Bladder | 2 | 2010 | 245 | 0.140 |
Why?
|
Overweight | 2 | 2008 | 116 | 0.140 |
Why?
|
Child | 8 | 2017 | 6930 | 0.140 |
Why?
|
Carcinoma, Ductal | 1 | 2015 | 18 | 0.130 |
Why?
|
Carcinoma, Acinar Cell | 1 | 2015 | 11 | 0.130 |
Why?
|
Ear Canal | 1 | 2015 | 13 | 0.130 |
Why?
|
Learning Curve | 1 | 2015 | 18 | 0.130 |
Why?
|
Probability | 4 | 2010 | 352 | 0.130 |
Why?
|
General Surgery | 2 | 2008 | 229 | 0.130 |
Why?
|
Operative Time | 1 | 2015 | 126 | 0.130 |
Why?
|
Logistic Models | 5 | 2011 | 1179 | 0.120 |
Why?
|
Neoplasm Grading | 4 | 2016 | 357 | 0.120 |
Why?
|
Population Surveillance | 1 | 2015 | 214 | 0.120 |
Why?
|
Predictive Value of Tests | 7 | 2016 | 1655 | 0.120 |
Why?
|
Neoplasm Invasiveness | 3 | 2016 | 552 | 0.120 |
Why?
|
Age Factors | 6 | 2013 | 1828 | 0.120 |
Why?
|
Antineoplastic Agents | 2 | 2011 | 2360 | 0.120 |
Why?
|
Organ Size | 3 | 2010 | 363 | 0.110 |
Why?
|
Brachytherapy | 2 | 2004 | 119 | 0.110 |
Why?
|
Diagnostic Errors | 1 | 2013 | 158 | 0.100 |
Why?
|
Incidence | 5 | 2015 | 1543 | 0.100 |
Why?
|
Anticoagulants | 1 | 2015 | 406 | 0.100 |
Why?
|
Ileum | 2 | 2010 | 159 | 0.100 |
Why?
|
Quality of Life | 3 | 2008 | 1581 | 0.100 |
Why?
|
Pain, Postoperative | 1 | 2014 | 240 | 0.100 |
Why?
|
Chemoprevention | 1 | 2011 | 92 | 0.100 |
Why?
|
Kidney | 3 | 2009 | 1128 | 0.100 |
Why?
|
Urinary Reservoirs, Continent | 1 | 2011 | 14 | 0.100 |
Why?
|
Ostomy | 1 | 2011 | 15 | 0.100 |
Why?
|
Apoptosis | 1 | 1998 | 1690 | 0.100 |
Why?
|
Cystostomy | 1 | 2011 | 15 | 0.100 |
Why?
|
Physicians | 2 | 2009 | 672 | 0.100 |
Why?
|
Ventriculoperitoneal Shunt | 1 | 2010 | 22 | 0.100 |
Why?
|
Risk Assessment | 5 | 2012 | 2213 | 0.090 |
Why?
|
Urodynamics | 3 | 2008 | 122 | 0.090 |
Why?
|
Frozen Sections | 1 | 2010 | 48 | 0.090 |
Why?
|
Immediate-Early Proteins | 1 | 2011 | 164 | 0.090 |
Why?
|
Carcinoma | 1 | 2013 | 436 | 0.090 |
Why?
|
Nephrectomy | 3 | 2007 | 290 | 0.090 |
Why?
|
Wolffian Ducts | 1 | 2009 | 7 | 0.090 |
Why?
|
Anesthesia | 2 | 2009 | 163 | 0.090 |
Why?
|
Femoral Artery | 1 | 2009 | 81 | 0.090 |
Why?
|
Intraoperative Complications | 2 | 2009 | 185 | 0.080 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2008 | 468 | 0.080 |
Why?
|
Reoperation | 2 | 2009 | 594 | 0.080 |
Why?
|
Radioimmunodetection | 1 | 2008 | 13 | 0.080 |
Why?
|
Aortic Aneurysm, Abdominal | 1 | 2009 | 112 | 0.080 |
Why?
|
Creatinine | 1 | 2009 | 294 | 0.080 |
Why?
|
Neuromuscular Diseases | 1 | 2008 | 30 | 0.080 |
Why?
|
Perioperative Care | 1 | 2009 | 162 | 0.080 |
Why?
|
Aorta | 1 | 2009 | 281 | 0.080 |
Why?
|
Arthritis | 1 | 2008 | 46 | 0.080 |
Why?
|
Prognosis | 5 | 2016 | 3639 | 0.080 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2008 | 65 | 0.080 |
Why?
|
Patient Selection | 1 | 2011 | 676 | 0.080 |
Why?
|
Minimally Invasive Surgical Procedures | 1 | 2009 | 237 | 0.080 |
Why?
|
Occupational Diseases | 1 | 2008 | 55 | 0.080 |
Why?
|
Fatty Acids, Omega-6 | 1 | 2007 | 9 | 0.070 |
Why?
|
Medical Illustration | 1 | 2007 | 16 | 0.070 |
Why?
|
Intestines | 1 | 2010 | 411 | 0.070 |
Why?
|
Contracture | 1 | 2006 | 18 | 0.070 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2009 | 208 | 0.070 |
Why?
|
Lymph Nodes | 1 | 2010 | 533 | 0.070 |
Why?
|
Urologic Neoplasms | 1 | 2007 | 77 | 0.070 |
Why?
|
Cohort Studies | 4 | 2020 | 2738 | 0.070 |
Why?
|
Urinary Bladder Diseases | 1 | 2006 | 41 | 0.070 |
Why?
|
Salvage Therapy | 1 | 2008 | 233 | 0.070 |
Why?
|
Prostatic Hyperplasia | 2 | 1998 | 88 | 0.070 |
Why?
|
Fatty Acids, Omega-3 | 1 | 2007 | 51 | 0.070 |
Why?
|
Chi-Square Distribution | 1 | 2007 | 358 | 0.070 |
Why?
|
Fellowships and Scholarships | 1 | 2007 | 110 | 0.070 |
Why?
|
United States | 2 | 2015 | 6582 | 0.070 |
Why?
|
Female | 11 | 2010 | 44218 | 0.070 |
Why?
|
Regression Analysis | 3 | 2013 | 593 | 0.060 |
Why?
|
Carcinoma, Medullary | 1 | 2004 | 11 | 0.060 |
Why?
|
Risk Factors | 5 | 2011 | 5251 | 0.060 |
Why?
|
Analysis of Variance | 3 | 2012 | 901 | 0.060 |
Why?
|
Radiotherapy, Conformal | 1 | 2004 | 83 | 0.060 |
Why?
|
Obesity | 2 | 2008 | 943 | 0.060 |
Why?
|
Survival Rate | 3 | 2015 | 1849 | 0.050 |
Why?
|
Child, Preschool | 3 | 2011 | 3612 | 0.050 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2004 | 176 | 0.050 |
Why?
|
Immunohistochemistry | 3 | 2012 | 1760 | 0.050 |
Why?
|
Kidney Neoplasms | 2 | 2007 | 619 | 0.050 |
Why?
|
Genital Neoplasms, Male | 1 | 2021 | 11 | 0.050 |
Why?
|
Sildenafil Citrate | 1 | 2000 | 23 | 0.050 |
Why?
|
Survival Analysis | 2 | 2016 | 1532 | 0.050 |
Why?
|
Sulfones | 1 | 2000 | 43 | 0.050 |
Why?
|
Purines | 1 | 2000 | 90 | 0.050 |
Why?
|
Penis | 1 | 2000 | 56 | 0.050 |
Why?
|
Hot Flashes | 1 | 2000 | 11 | 0.050 |
Why?
|
Leuprolide | 1 | 2000 | 29 | 0.050 |
Why?
|
Health Surveys | 1 | 2000 | 236 | 0.040 |
Why?
|
Algorithms | 2 | 2007 | 1824 | 0.040 |
Why?
|
Tumor Cells, Cultured | 2 | 1998 | 1041 | 0.040 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2000 | 150 | 0.040 |
Why?
|
Estrogens | 1 | 2000 | 200 | 0.040 |
Why?
|
Neoplasm, Residual | 2 | 2012 | 162 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2004 | 1200 | 0.040 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 1998 | 65 | 0.040 |
Why?
|
Gene Expression Profiling | 1 | 2004 | 1388 | 0.040 |
Why?
|
Doxazosin | 1 | 1997 | 1 | 0.040 |
Why?
|
Risk | 2 | 2010 | 657 | 0.040 |
Why?
|
Adrenergic alpha-Antagonists | 1 | 1997 | 31 | 0.040 |
Why?
|
Intraoperative Period | 2 | 2008 | 90 | 0.040 |
Why?
|
Early Detection of Cancer | 1 | 2021 | 395 | 0.040 |
Why?
|
Neoplasm Transplantation | 1 | 1998 | 393 | 0.040 |
Why?
|
Health Care Rationing | 1 | 2017 | 83 | 0.040 |
Why?
|
Feasibility Studies | 2 | 2010 | 752 | 0.040 |
Why?
|
Surgical Procedures, Operative | 1 | 1998 | 182 | 0.040 |
Why?
|
Plant Extracts | 1 | 1998 | 244 | 0.030 |
Why?
|
Mice, Nude | 1 | 1998 | 791 | 0.030 |
Why?
|
Cell Survival | 1 | 1998 | 972 | 0.030 |
Why?
|
Rats | 2 | 1998 | 3998 | 0.030 |
Why?
|
Adolescent | 3 | 2011 | 8959 | 0.030 |
Why?
|
Relative Biological Effectiveness | 2 | 2004 | 13 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 1998 | 1928 | 0.030 |
Why?
|
Biopsy, Large-Core Needle | 1 | 2013 | 14 | 0.030 |
Why?
|
Databases, Factual | 1 | 2016 | 813 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2008 | 349 | 0.030 |
Why?
|
Specimen Handling | 1 | 2013 | 98 | 0.030 |
Why?
|
Likelihood Functions | 1 | 2013 | 251 | 0.030 |
Why?
|
Chicago | 1 | 2016 | 1378 | 0.030 |
Why?
|
Infant | 1 | 1998 | 3051 | 0.030 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2011 | 40 | 0.020 |
Why?
|
Tissue Array Analysis | 1 | 2011 | 124 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2010 | 59 | 0.020 |
Why?
|
Spinal Dysraphism | 1 | 2010 | 17 | 0.020 |
Why?
|
Receptors, Androgen | 1 | 2011 | 113 | 0.020 |
Why?
|
Intraoperative Care | 1 | 2010 | 82 | 0.020 |
Why?
|
Receptors, Glucocorticoid | 1 | 2011 | 120 | 0.020 |
Why?
|
Combined Modality Therapy | 2 | 2004 | 1677 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2012 | 850 | 0.020 |
Why?
|
Life Expectancy | 1 | 2010 | 85 | 0.020 |
Why?
|
Body Mass Index | 1 | 2013 | 755 | 0.020 |
Why?
|
Fasciotomy | 1 | 2009 | 16 | 0.020 |
Why?
|
Lymphocele | 1 | 2009 | 6 | 0.020 |
Why?
|
Vas Deferens | 1 | 2009 | 7 | 0.020 |
Why?
|
Aortography | 1 | 2009 | 62 | 0.020 |
Why?
|
Databases as Topic | 1 | 2009 | 92 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2009 | 226 | 0.020 |
Why?
|
Incidental Findings | 1 | 2009 | 96 | 0.020 |
Why?
|
Calibration | 1 | 2008 | 99 | 0.020 |
Why?
|
Urography | 1 | 2008 | 45 | 0.020 |
Why?
|
Cystoscopy | 1 | 2008 | 35 | 0.020 |
Why?
|
Ureter | 1 | 2009 | 92 | 0.020 |
Why?
|
Internship and Residency | 1 | 2017 | 1011 | 0.020 |
Why?
|
Area Under Curve | 1 | 2008 | 333 | 0.020 |
Why?
|
Glomerular Filtration Rate | 1 | 2009 | 273 | 0.020 |
Why?
|
Mathematics | 1 | 2007 | 190 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2011 | 1696 | 0.020 |
Why?
|
Swine | 1 | 2009 | 559 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2011 | 1561 | 0.020 |
Why?
|
In Vitro Techniques | 1 | 2009 | 991 | 0.020 |
Why?
|
Jamaica | 1 | 2007 | 5 | 0.020 |
Why?
|
Mice | 2 | 1998 | 11439 | 0.020 |
Why?
|
Postoperative Period | 1 | 2008 | 302 | 0.020 |
Why?
|
Animals | 3 | 2009 | 26652 | 0.020 |
Why?
|
Equipment Design | 1 | 2008 | 405 | 0.020 |
Why?
|
Demography | 1 | 2007 | 177 | 0.020 |
Why?
|
Odds Ratio | 1 | 2008 | 676 | 0.020 |
Why?
|
Fatty Acids | 1 | 2007 | 130 | 0.020 |
Why?
|
ROC Curve | 1 | 2008 | 752 | 0.020 |
Why?
|
Dietary Fats | 1 | 2007 | 135 | 0.020 |
Why?
|
Acute Disease | 1 | 2007 | 827 | 0.020 |
Why?
|
Recurrence | 1 | 2008 | 1136 | 0.020 |
Why?
|
Gene Library | 1 | 2004 | 131 | 0.010 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2004 | 188 | 0.010 |
Why?
|
Fatal Outcome | 1 | 2004 | 295 | 0.010 |
Why?
|
Radiotherapy Dosage | 1 | 2003 | 468 | 0.010 |
Why?
|
Administration, Cutaneous | 1 | 2000 | 58 | 0.010 |
Why?
|
Disease Progression | 1 | 2004 | 1458 | 0.010 |
Why?
|
Biomarkers, Tumor | 1 | 2007 | 1465 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2009 | 2583 | 0.010 |
Why?
|
Neomycin | 1 | 1998 | 7 | 0.010 |
Why?
|
Karyotyping | 1 | 1998 | 250 | 0.010 |
Why?
|
Mice, SCID | 1 | 1998 | 254 | 0.010 |
Why?
|
Antibiotics, Antineoplastic | 1 | 1998 | 114 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 1998 | 592 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 1998 | 1054 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 1998 | 2262 | 0.000 |
Why?
|